Nonalcoholic Fatty Liver Disease

The link between two metal ion transporters and MRI based corrected Tl demonstrated a new mechanism in steatohepatitis, according to a recently published article.

For patients with nonalcoholic fatty liver disease, a positive anti-hepatitis B core antibody was correlated with cirrhosis and hepatocellular carcinoma, according to a study published in the American Journal of Gastroenterology.

Beta-cell function may deteriorate in the presence of excess fat in the liver for adults with and without diabetes, according to findings published in the Journal of Diabetes Investigation.

Biopsy-confirmed fibrosis was associated with risk for mortality and liver-related morbidity in patients with NAFLD, regardless of confounding factors and in patients with NASH, according to study results.

Akcea Therapeutics and Ionis Pharmaceuticals announced that a phase 2 study of AKCEA-ANGPTL3-LRx for the treatment of patients with hypertriglyceridemia, type 2 diabetes and nonalcoholic fatty liver disease met its primary endpoint of significant triglyceride lowering.

MAUI, HAWAII — A novel study that examined the link between psoriasis and CVD was one of several studies summarized at Maui Derm for Dermatologists 2020 that examined psoriasis’ link to several co-morbidities.

The risk of fibrosis is highest in young adults with harmful drinking patterns and steatosis, according to data from a population-based study.

Axcella released an update from the ongoing clinical study of two potential therapies for nonalcoholic fatty liver disease that showed the compounds were safe, well-tolerated, and demonstrated relevant clinical response, according to a press release.

NASHNET has designated the Central Virginia VA Health Care System as its eighth founding charter member and “center of excellence” in recognition of the system’s work in fatty liver disease, according to a press release.

Both the fatty liver inhibition of progression algorithm and the steatosis activity and fibrosis scoring system identified distinct clinical and biological profiles of disease severity among patients with suspected nonalcoholic fatty liver disease.